International conferences and seminars

5th Immunotherapeutics & Immunomonitoring Conference

Ron Levy, Professor of Medicine & Chief, Division of Oncology at Stanford University will give the Keynote Presentation on "Antibody Therapy of Cancer: Targeting the Cancer Cell and Targeting the Immune System" at the 5th Immunotherapeutics & Immunomonitoring Conference to be held on Jan 31 - Feb 1, 2013 in San Diego, CA. Monoclonal antibodies can be therapeutic for cancer by carrying drugs, toxins or radioactive agents. They can work in consort with NK cells and macrophages to induce antibody-dependent cellular cytotoxicy (ADCC) that targets the killer cells, inducing it to kill more efficiently. Dr. Levy is currently conducting clinical trials to test this concept. If successful, monoclonal antibody therapy may take a great leap forward.

The 5th Immunotherapeutics & Immunomonitoring Conference is part of the 2nd Novel Immunotherapeutics Summit, which consists of this and three other tracks:

11th Cytokines & Inflammation
2nd Allergy Research & Drug Discovery
Immunotoxicity & Immunogenicity

Leading experts from the scientific and clinical arenas and industry will present novel findings and developments in the constantly changing area of immunological assays and procedures. They will also discuss recent advances in immunotherapy, as they relate to various immunotherapy modalities, specific cancers, cell subsets, animal models, and tumor microenvironment. Potential clinical feasibility and commercial potential of the newest data obtained from leading biomedical research laboratories will also be discussed.

Sign up today and save 10% off the regular price!
Or Register for the whole Novel Immunotherapeutics Summit to get access to all four tracks.
Bring your team! Register 2 people at the regular price, bring a 3rd person for free! Use discount code rcdvb.

Submit an abstract by Dec 30, 2012

SPEAKERS

Ron Levy, Professor of Medicine and Chief, Division of Oncology, Stanford University - KEYNOTE

Helen Sabzevari, Global Head of Immuno-Oncology, EMD Serono - FEATURED

Puja Sapra, Director, Oncology Research Unit, Pfizer - FEATURED

Ronald Swanson, Senior Director, Biologics Research, Janssen R&D - FEATURED

Nicholas Valiante, Head of Immunology, U.S. & Global Head of Immuno-Therapy, Novartis - FEATURED

Yihong Yao, Director, Head Of Pharmacogenomics and Bioinformatics, Translational Sciences, MedImmune - FEATURED

Margaret Ackerman, Assistant Professor of Engineering, Thayer School of Engineering at Dartmouth

Kate Broderick, Director of Research & Development, Inovio

Pirouz Daftarian, Research Assistant Professor of Microbiology and Immunology, University of Miami

Don Diamond, Director, Translational Vaccine Research; Professor, Virology, City of Hope

Iqbal Grewal, Chief Scientific Officer, ImmunGene Inc.

Debraj GuhaThakurta, Senior Scientist II & Group Leader, Systems Biology, Dendreon

Ulrich Hoffmueller, Chief Business Officer and Founder, Epiontis

Yuhui Huang, Research Fellow, Harvard Medical School

Syd Johnson, Vice President, Antibody Engineering, Macrogenics

Roman Kischel, Principal Scientist, Amgen

Keith Knutson, Associate Professor, Department of Immunology, Mayo Clinic

Reiner Laus, President and Chief Executive Officer, BN ImmunoTherapeutics

Sattva Neelapu, Associate Professor, Department of Lymphoma and Myeloma, The University of Texas M. D. Anderson Cancer Center

Sicco Popma, Scientific Director, Stem Cell Research, Janssen R&D

Thomas Schall, President and Chief Executive Officer, Chemocentryx

Jeffrey Schlom, Chief, Laboratory of Tumor Immunology & Biology, National Cancer Institute, National Institutes of Health

Prediman Krishan Shah, Director, Cardiology & Artherioschlerosis Research Center, Cedars Sinai Medical Center

Pablo Umana, Head of Research, Glycart AG (Roche Group)

Steffen Walter, Director & Head, Immunology, Immatics Biotechnologies GmbH

Albert Wong, Professor, Stanford University Medical Center